Abstract | BACKGROUND AND PURPOSE: MATERIALS AND METHODS:
CpG ODN 1826 (100 microg) was given sc three times: when leg tumors were 6mm, when they grew to 8mm and again 1 week later. DOC (33 mg/kg iv) and local tumor radiation (10Gy) were given when tumors were 8mm. Effects of the treatments were assayed by tumor growth delay, defined as days for tumors to grow from 8 to 12 mm in diameter. RESULTS: Treatment with CpG ODN 1826 resulted in strongly enhanced response of FSa tumors to radiation and MCa-K tumors to the chemotherapeutic agent DOC. Enhancement of tumor treatment response was demonstrated by a strong prolongation in the primary tumor treatment endpoint, tumor growth delay. Coincidentally, this treatment also resulted in a higher rate of tumor cure than that observed after tumor radiotherapy or chemotherapy alone. When all three agents were combined the effect was comparable to that of the combination of CpG ODN 1826 with radiation in the case of FSa or of the combination of CpG ODN 1826 with DOC in the case of MCa-K. CONCLUSION: Overall results show that CpG ODN 1826 can markedly improve tumor response to radiation and chemotherapy (DOC), suggesting that CpG ODNs have potential to be beneficial when used singly or in combination with other standard treatment modalities such as taxane chemotherapy, radiotherapy or both.
|
Authors | Kathryn A Mason, Robert Neal, Nancy Hunter, Hisanori Ariga, Kian Ang, Luka Milas |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 80
Issue 2
Pg. 192-8
(Aug 2006)
ISSN: 0167-8140 [Print] Ireland |
PMID | 16905212
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- CpG ODN 1826
- Oligodeoxyribonucleotides
- Taxoids
- Docetaxel
- DNA
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Combined Modality Therapy
- DNA
(administration & dosage, pharmacology)
- Docetaxel
- Drug Synergism
- Female
- Lymphocytes, Tumor-Infiltrating
(drug effects, radiation effects)
- Male
- Mammary Neoplasms, Experimental
(drug therapy, genetics, pathology, radiotherapy)
- Mice
- Neoplasms, Experimental
(drug therapy, genetics, radiotherapy)
- Oligodeoxyribonucleotides
- Sarcoma, Experimental
(drug therapy, genetics, pathology, radiotherapy)
- Taxoids
(administration & dosage, pharmacology)
|